Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.
Eptifibatide is a platelet aggregation inhibitor that works by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. It is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting.)
The premixed formulation was developed using Baxter’s GALAXY container technology. GALAXY is a non-PVC and non-DEHP system that helps extend the shelf-life of the premixed medicine when kept at room temperature; it can be stored at 25°C (77°F) for up to 2 months.
“By adding more essential premix medicines – like eptifibatide – to Baxter’s broad portfolio, we can help support pharmacy efficiency, reduce waste and enhance patient safety,” stated Robert Felicelli, president of Baxter Pharmaceuticals.
Eptifibatide Injection is available in 75mg/100mL and 200mg/100mL strengths in single-dose GALAXY containers.
For more information call (866) 888-2472 or visit Baxter.com.
This article originally appeared on MPR